Wall Street Analysts Think Adma Biologics (ADMA) Could Surge 60.24%: Read This Before Placing a Bet

Group 1 - Adma Biologics (ADMA) shares have increased by 23.3% in the past four weeks, closing at $19.14, with a mean price target of $30.67 indicating a potential upside of 60.2% [1] - The average price targets range from a low of $30.00 to a high of $32.00, with a standard deviation of $1.15, suggesting a strong agreement among analysts [2] - Analysts show strong consensus on ADMA's ability to report better earnings than previously predicted, which supports the potential for stock upside [4][11] Group 2 - The Zacks Consensus Estimate for ADMA's current year earnings has increased by 1.6% over the last 30 days, with no negative revisions [12] - ADMA holds a Zacks Rank 2 (Buy), placing it in the top 20% of over 4,000 ranked stocks based on earnings estimates [13] - While the consensus price target may not be entirely reliable, it does provide a useful guide for potential price movement [14]